Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “IV infusion of 200,000,000 of neuroinduced mesynchimal stem cells at week 1 of the trial period”In the company’s words, NCT07465198 on ClinicalTrials.gov
- Tested for
- MSA - Multiple System Atrophy, MSA
- Main trialPhase 2
- “This study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. The trial will evaluate functional outcomes, motor performance, and quality of life compared to placebo/controlled group.”In the company’s words, NCT07465198 on ClinicalTrials.gov
Other drugs for MSA - Multiple System Atrophy
- AmpreloxetineTheravance Biopharma · Phase 3
- HOMSC300Cytora Ltd. · Phase 1
Coming up1
- 1 Sep 2029Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 1 Sep 2029 | Autologous Stem Cell Therapy in Patients With Multiple System Atrophy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026